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Background: This study assessed the proportion of risk-stratified Korean patients with dyslipidemia achieving their low-density li-
poprotein cholesterol (LDL-C) targets as defined by the European Society of Cardiology/European Atherosclerosis Society (ESC/
EAS) (2011) guidelines while receiving lipid-modifying treatments (LMTs).
Methods: In this multicenter, cross-sectional, observational study, we evaluated data from Korean patients aged ≥19 years who 
were receiving LMTs for ≥3 months and had an LDL-C value within the previous 12 months on the same LMT. Data were collected 
for demographics, cardiovascular (CV) risk factors, medical history, and healthcare consumption. Patients were risk-stratified ac-
cording to the ESC Systematic COronary Risk Evaluation (SCORE) chart and LDL-C target achievement rate was assessed. 
Results: Guideline-based risk-stratification of the 1,034 patients showed the majority (72.2%) to be in the very high-risk category. 
Investigators’ assessment of risk was underestimated in 71.6% compared to ESC/EAS guidelines. Overall LDL-C target achieve-
ment rate was 44.3%; target achievement was the highest (66.0%) in moderate-risk patients and the lowest (39.0%) in very high-risk 
patients. Overall 97.1% patients were receiving statin therapy, mostly as a single-agent (89.2%). High-intensity statins and the high-
est permissible dose of high-intensity statins had been prescribed to only 9.1% and 7.3% patients in the very high-risk group, respec-
tively. Physician satisfaction with patients’ LDL-C levels was the primary reason for non-intensification of statin therapy.
Conclusion: Achievement of target LDL-C level is suboptimal in Korean patients with dyslipidemia, especially in those at very 
high-risk of CV events. Current practices in LMTs need to be improved based on precise CV risk evaluation posed by dyslipidemia.
Keywords: Dyslipidemias; Cholesterol, LDL; Hydroxymethylglutaryl-CoA reductase inhibitors; Practice guideline; Risk assess-
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INTRODUCTION
Dyslipidemia, characterized by abnormal levels of serum lipids, 
is a major established risk factor for cardiovascular disease (CVD) 
[1] and cerebrovascular disease [2] in Korea. At present, these 
diseases rank as the second- and third-leading cause of mortality 
in Koreans [3]. According to the results of the Korea National 
Health and Nutrition Examination Survey (KNHANES), the 
age-standardized prevalence of dyslipidemia in Korea has risen 
steadily from 54.0% in 1998 to 59.0% in 2010 [4]. For the peri-
od 2005 to 2010, awareness and treatment rates for dyslipid-
emia in Korea were also found to have gradually increased to 
13.7% and 7.4%, respectively [4]. However, these can still be 
considered as suboptimal.
Various epidemiological studies have shown that low-density 
lipoprotein (LDL) has negative implications in CVD [5-7]. Ko-
rean patients with dyslipidemia have been reported to have a 
propensity for relatively higher triglycerides (TG) and lower 
high-density lipoprotein cholesterol (HDL-C) levels. However, 
in recent years, the incidence of hypercholesterolemia and ele-
vated LDL-cholesterol (LDL-C) levels has been increasing in 
parallel, without any decrease in hypertriglyceridemia or hypo-
HDL-cholesterolemia [8]. Further KNHANES database has 
shown that approximately 10.0% of Korean adults have LDL-C 
levels that needed to be pharmacologically lowered, and 19.9% 
have LDL-C levels that needed therapeutic lifestyle modifica-
tions [9]. Consequently, dyslipidemia stands to substantially in-
crease the cardiovascular (CV) risk in the Korean population 
and needs to be considered as a major health concern in the Ko-
rean setting. 
Considering the role of LDL-C as a crucial modifiable CV 
risk factor, various international guidelines recommend lower-
ing of LDL-C levels to minimize the risk of CV events [10-13]. 
The recently formulated guidelines from the Committee of 
Clinical Practice of the Korean Society of Lipid and Atheroscle-
rosis for the Management of Dyslipidemia [14] also recommend 
the reduction of LDL-C levels to target levels or lower as the 
first goal for management of dyslipidemia. The discovery of 
statins has revolutionized dyslipidemia treatment and statins are 
known to substantially reduce LDL-C levels and reduce CV 
complications and mortality [15-18]. Besides interfering with 
the biosynthesis of cholesterol, statins also increase receptor-
mediated uptake of circulating LDL and its precursors [19]. De-
spite the establishment of guidelines and proven effectiveness 
of statins for more than a decade, the achievement of LDL-C 
and total cholesterol (TC) targets in Koreans is suboptimal with 
current therapeutic options [20,21]. To address this issue, it is 
vital to assess existing practice patterns for the treatment of dys-
lipidemia in real clinical settings. A major limitation to such an 
undertaking is the paucity of data which is applicable to Korea. 
A recent study in Korean real-world practice has demonstrated 
good compliance for at least 18 months in patients who had 
been started with statins at the fixed doses [22]; however, the 
study was performed at a single institution and lacks generaliz-
ability. Moreover, the indices of metabolic syndrome in Korea 
have historically been TG and HDL-C [9], hence it is not possi-
ble to infer LDL-C levels in the general population from the 
KNHANES database [23].
The International ChoLesterol Management Practice Study 
(ICLPS) was an observational study [24] designed to ascertain 
the proportion of patients with moderate to very high CV risk 
reaching LDL-C targets as defined by the European Society of 
Cardiology/European Atherosclerosis Society (ESC/EAS) 
(2011) guidelines [25] in a real-world setting. In this report, we 
describe the results from the Korean cohort of the ICLPS. In ad-
dition, we also attempt to identify whether the treatment of dys-
lipidemia in actual practice in Korea differed from that recom-
mended by the guidelines.
METHODS
Study design 
Data included in the reported sub-analysis was collected from 
the Korean cohort of ICLPS—an international, multicenter, 
cross-sectional, observational study conducted at various loca-
tions in Eurasia, Asia, Africa, Middle-East, and South America 
[24]. 
Study investigators were primarily those physicians who were 
representatives in the medical community who managed pa-
tients with dyslipidemia and included cardiologists, endocrinol-
ogists, gerontologists, internists, and general practitioners. In-
vestigators were selected randomly and independently from a 
pre-established list of physicians that was meant to ensure ap-
propriate proportion of all specialties managing patients with 
dyslipidemia. 
Patient recruitment and data collection
Patients eligible for inclusion in the study were ≥19 years of 
age, receiving lipid-modifying treatments (LMTs) for at least 3 
months prior to enrollment, and had an LDL-C value measured 
<12 months prior to enrollment while on the same LMT. Use of 
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi-
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tors within 6 months prior to enrollment as well as participation 
in other trials simultaneously were grounds for study exclusion. 
The present study was approved by the Institutional Review 
Board of each study site (IRB number: DSMC 2015-06-009, B- 
1506-304-301, H-1506-102-682, NHIMC 2015-06-008, HYUH 
2015-06-010, H-1506-011-030, 2015GR-0156, 15-098, KUGH 
2015-06-005, DSMC 2015-06-013, 2015GR-0141, SMC 2015-
07-037-001, UUH 2015-08-007, CHOSUN 2015-06-015, 2015-
12-151, 4-2015-1029, 2015GR-00326, 16-0002, CNUH 2016-
001-022) and was conducted according to the Declaration of 
Helsinki. All study patients had to provide informed consent. In 
order to reduce bias, patients were recruited consecutively at 
each study site over a limited period of time (≤2 weeks). The 
study involved a single visit during enrollment with no subse-
quent follow-up. 
Data of investigators was collected including age and gender, 
specialty, years of practice, location, mean number of patients 
consulted per day (total and with hypercholesterolemia), guide-
lines adhered to, and definition of statin intolerance used. Data 
of patients in the Korean cohort was collected between August 
2015 and March 2016 and included demographics and socio-
economic profile, physical examination, CV risk factors, dyslip-
idemia and other medical history, laboratory values, ongoing 
medications, healthcare consumption (past 12 months), level of 
CV risk, and target LDL-C value. 
Risk stratification of patients was conducted according to the 
ESC Systematic COronary Risk Evaluation (SCORE) chart [26] 
and LDL-C target for individual patients was ascertained as de-
fined by ESC/EAS (2011) guidelines (Supplemental Table S1) 
[25]. Values of both parameters, as defined by the guidelines and 
as assessed by the investigators, were compared to determine if 
any gap existed between the guideline and the actual practice. 
Familial hypercholesterolemia (FH) was assessed/diagnosed us-
ing the Dutch Lipid Clinic Network diagnostic criteria [27]. Pri-
mary/familial dyslipidemia was defined at least one of the fol-
lowing: (1) FH (heterozygous, homozygous, or unknown), (2) 
first degree relative with known LDL-C above 95th percentile 
for age and gender, (3) first degree relative with tendinous xan-
thomata and/or arcus cornealis. The reason for not prescribing 
the highest dose of statins was assessed by a questionnaire 
which was configured to select one of three reasons; physician 
satisfaction, medically inappropriate, statin intolerance. 
Statistical analysis
The population for analysis consisted of all patients who met 
the inclusion criteria at enrollment in this study. Furthermore, 
any investigator who recruited at least one patient was included 
in analysis of physician profile (Supplemental Table S2). Sam-
ple size of the international study [24] was calculated in order to 
ensure a sufficient precision in the assessment of the qualitative 
data and the study planned to recruit approximately 11,000 pa-
tients from around 700 sites in 35 countries. 
Descriptive statistics using counts and percentages for cate-
gorical variables and mean, median, standard deviation (SD), 
and range for continuous variables, were used for data analysis. 
All statistical analyses were conducted using SAS version 9.2 
(SAS Institute, Cary, NC, USA). 
RESULTS
Investigator profile and patient characteristics
Study investigators (n=19) were mostly male (n=16, 84.2%), 
cardiologists (n=9, 47.4%), or endocrinologists (n=6, 31.6%), 
and had ≥15 years of clinical experience. All investigators re-
ported following guidelines for management of dyslipidemia 
and the most common were those by the American College of 
Cardiology/American Heart Association (ACC/AHA) (n/total 
number=13/19, 68.4%) and the ESC/EAS (n/total num-
ber=6/19, 31.6%). Adherence to domestic [14] and other inter-
national guidelines was reported by four (21.6%) and three 
(15.8%) investigators, respectively. Some investigators reported 
following multiple guidelines. About half (52.6%), 36.8% and 
10.5% of physicians defined patients as “statin-intolerant” when 
patients were intolerant to one, two, and more than two statins, 
respectively. 
Investigators enrolled 1,069 patients across Korea in between 
August 2015 and March 2016 and data from 1,034 was eligible 
for analysis. Study population comprised 54.9% (n=568) males 
and 45.1% females (n=466) (Table 1). The mean age±SD of 
study population was 63.3±10.4 years and 49.7% of the pa-
tients were in the age range ≥45 to <65 years. 
Commonly prevalent CV risk factors were hypertension 
(n=730, 70.6%), lack of physical activity (n=621, 60.1%), and 
diabetes (n=517, 50.0%) (Table 1). Patients in the very high-
risk category also had a high prevalence of coronary artery dis-
ease (CAD; n/total number=424/747; 56.8%). Over half of the 
very high-risk patients with CAD presented with acute coronary 
syndrome (ACS)/myocardial infarction (MI) (n=254, 59.9%) 
or percutaneous coronary intervention (n=246, 58.1%). Elevat-
ed consumption of healthcare resources was reported in 22.0% 
(n=227) of the overall patients and in 25.3% (n/total num-
ber=189/747) of the very high-risk patients.
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Risk stratification of study patients according to ESC/EAS 
(2011) guidelines
Risk stratification of study patients (n=1,034) according to ESC/
EAS (2011) guidelines classified the patients as—747 (72.2%) 
with very high-risk, 178 (17.2%) with high-risk, 47 (4.5%) with 
moderate-risk, and one (0.1%) with low-risk. A total of 61 
(5.9%) patients were deemed non-assessable for risk according 
to the guidelines (Fig. 1A). The investigators’ assessment of risk 
was consistent with guideline-based risk assessment in only 
20.1% (n/total number=150/747) very high-risk patients, 46.1% 
(n/total number=82/178) high-risk patients, and 48.8% (n/total 
number=23/47) moderate-risk patients (Table 2). Overall, only 
26.2% (n/total number=255/973) of physician’s assessment 
were consistent with the guidelines and in most of the cases (n/
total number=697/973, 71.6%), and physician underestimated 
the risk of patients compared to the guideline (Fig. 1B).
Serum LDL-C profile and lipid-modifying treatments 
prescribed
A total of 796 (77.3%) patients had a history of dyslipidemia for 
a mean±SD duration of 4.9±3.6 years since diagnosis. Of these 
patients, 13.3% (n=137) and 47.0% (n=485) were reported to have 
primary (or familial) and secondary hypercholesterolemia, re-
spectively. At first diagnosis, the mean±SD values for lipid param-














Age in years 30.0 56.2±7.9 60.9±9.5 64.5±10.4 62.6±11.0 63.3±10.4
Gender
   Male 0 12 (25.5) 76 (42.7) 455 (60.9) 25 (41.0) 568 (54.9)
   Female 1 (100) 35 (74.5) 102 (57.3) 292 (39.1) 36 (59.0) 466 (45.1)
History of dyslipidemia 1 (100) 47 (100) 167 (93.8) 536 (72.1) 45 (73.8) 796 (77.0)
Time in years since diagnosis of dyslipidemia 1.0 4.1±3.0 5.1±3.6 5.0±3.7 4.2±2.8 4.9±3.6
Prevalence of CV risk factors 
   Hypertensionb 1 (100) 22 (46.8) 100 (56.2) 569 (76.2) 38 (62.3) 730 (70.6)
   Lack of physical activityc 1 (100) 30 (63.8) 104 (58.4) 446 (59.7) 40 (65.6) 621 (60.1)
   Diabetesd 0 0 140 (78.7) 377 (50.5) 0 517 (50.0)
   Regular alcohol consumptione 0 4 (8.5) 32 (18.0) 143 (19.1) 11 (18.0) 190 (18.4)
   Familial history of CVDf 0 7 (14.9) 32 (18.0) 137 (18.3) 12 (19.7) 188 (18.2)
   Current smokingg 0 1 (2.1) 19 (10.7) 116 (15.5) 8 (13.1) 144 (13.9)
CV comorbidities
   CAD 0 0 0 424 (56.8) 0 424 (41.0)
      ACS/MIh (n=424) NA NA NA 254 (59.9) NA 254 (59.9)
      PCIh (n=424) NA NA NA 246 (58.0) NA 246 (58.1)
      CABGh (n=424) NA NA NA 16 (3.8) NA 16 (3.8)
   Stroke 0 0 0 140 (18.7) 0 140 (13.5)
   CKDi 1 (100.0) 9 (19.1) 9 (5.1) 94 (12.6) 5 (8.2) 118 (11.4)
Values are expressed as mean±standard deviation or number (%).
CV, cardiovascular; CVD, cardiovascular disorder; CAD, coronary artery disease; ACS, acute coronary syndrome; MI, myocardial infarction; NA, not 
applicable; PCI, percutaneous intervention; CABG, coronary artery bypass graft; CKD, chronic kidney disease.
aPatients without a serious pathology classifying them as very high or high cardiovascular risk, and in whom the Systematic COronary Risk Evaluation 
(SCORE) could not be calculated due to missing data (most commonly baseline low-density lipoprotein cholesterol); bSystolic blood pressure ≥140 mm 
Hg and/or diastolic blood pressure ≥90 mm Hg or a previous history of hypertension; cPatient is not regularly involved in moderate (walking/cycling/
gardening) or strenuous exercise (jogging/football/vigorous swimming) for ≥4 hours each week; dType 1 or 2 diabetes mellitus; eConsumption ≥3 times 
a week; fCoronary and/or vascular disease <55 years of age in male and <60 years in female first-degree relatives; gCurrent smokers and individuals 
who smoked any tobacco in the previous 12 months (including those who have quit smoking within the previous 12 months); hOnly assessed in patients 
with CAD; iGFR <60 mL/min/1.73 m2.
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eters were: LDL-C, 138.2±40.3 mg/dL; TC, 215.9±45.9 mg/dL; 
HDL-C, 48.0±12.9 mg/dL; and TG, 179.3±123.7 mg/dL. In 
comparison, mean values for lipid parameters at enrollment were: 























































Moderate High Very high Not assessable
Fig. 1. (A) Comparison of risk stratification according to European Society of Cardiology (ESC) Systematic COronary Risk Evaluation 
(SCORE) chart [27] and physician judgement. (B) The matching pattern of physician judgement for risk stratification compared to ESC/Eu-
ropean Atherosclerosis Society (EAS) 2011 guidelines. Physician assessment overestimated and underestimated were defined as the physi-
cian’s risk assessment was higher and lower than the risk of the patients according to ESC/EAS guideline, respectively. 
A
B
Table 2. Risk Assessment According to ESC/EAS 2011 Guidelines versus Risk Assessment by Investigator













Low 0a 20 (42.6) 39 (21.9) 65 (8.7) 14 (23.0) 138 (13.3)
Moderate 1 (100) 23 (48.9)a 41 (23.0) 226 (30.3) 39 (63.9) 330 (31.9)
High 0 4 (8.5) 82 (46.1)a 306 (41.0) 6 (9.8) 398 (38.5)
Very high 0 0 16 (9.0) 150 (20.1)a 2 (3.3) 168 (16.2)
Values are expressed as number (%).
ESC, European Society of Cardiology; EAS, European Atherosclerosis Society.
aThe investigator’s risk assessment and the guidance-based risk assessment were the same.
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50.1±13.6 mg/dL; and TG, 136.2±93.0 mg/dL.
Statins were the most commonly prescribed LMTs, reported 
in 1,004 (97.1%) patients, mostly as monotherapy (n=922, 
89.2%) (Table 3). Of the patients using statins, 7.8% (n=78) of 
overall patients and 9.1% (n=66) of very high-risk patients were 
taking high-intensity statins. The maximum permissible dose of 
high-intensity statins had been prescribed to 7.4% (n=74) of 
overall patients and 7.3% (n=53) of very high-risk patients. The 
most common (84.5%) reason for not prescribing highest per-
missible dose of statins was cited as physician satisfaction with 
patient’s LDL-C levels from current dosage (Table 3).
LDL-C target achievement
Overall achievement of target LDL-C was reported in 44.3% (n/
total number=431/973) of the patients (Fig. 2). Proportions of 
patients attaining target LDL-C levels in each risk group were 
–66.0% (n/total number=31/47) in the moderate-risk group; 
61.2% (n/total number=109/178) in the high-risk group; and 
39.0% (n/total number=291/747) in the very high-risk group. 
Of the 129 patients who were statin-intolerant, 39.3% (n=55) 
had achieved their LDL-C target; in contrast to 45.2% (n/total 
number=376/832) of the remainder of the patients who were 
statin-tolerant. On the other hand, patients who had experienced 
ACS/MI in the 12 months preceding study enrollment had a 
lower rate of target achievement in comparison to those who 























Fig. 2. Target low-density lipoprotein cholesterol achievement ac-
cording to cardiovascular risk strata. Error bars represent 95% con-
fidence intervals. 















   Statins 1 (100) 47 (100) 169 (94.9) 729 (97.6) 58 (95.1) 1,004 (97.1)
   Fibrates 0 0 10 (5.6) 27 (3.6) 4 (6.6) 41 (4.0)
   Omega-3 fatty acids 0 2 (4.3) 8 (4.5) 29 (3.9) 1 (1.6) 40 (3.9)
   Cholesterol absorption inhibitors 0 6 (12.8) 6 (3.4) 19 (2.5) 0 31 (3.0)
   Others 0 0 0 6 (0.8) 0 6 (0.6)
Patients receiving high-intensity statinsb 0 2 (4.3) 9 (5.3) 66 (9.1) 1 (1.7) 78 (7.8)
Patients receiving highest permissible dose of statins 0 2 (4.3) 15 (8.9) 53 (7.3) 4 (6.9) 74 (7.4)
Reason for not prescribing the highest dose of statins 
   Assessed number of patients 1 45 154 664 54 918
   Physician satisfactionc 0 35 (77.8) 141 (91.6) 550 (82.8) 50 (92.6) 776 (84.5)
   Medically inappropriated 1 (100) 9 (20.0) 9 (5.8) 154 (23.2) 13 (24.1) 186 (20.3)
   Statin intolerancee 0 1 (2.2) 4 (2.6) 15 (2.3) 0 20 (2.2)
Values are expressed as number (%).
aPatients without a serious pathology classifying them as very high or high cardiovascular risk, and in whom the Systematic COronary Risk Evaluation 
(SCORE) could not be calculated due to missing data (most commonly baseline low-density lipoprotein cholesterol [LDL-C]); bAtorvastatin 40/80 mg or 
rosuvastatin 20/40 mg; cPhysician determined that the patient’s LDL-C levels were appropriate; dHigher dose not advisable due to patient’s clinical con-
dition; ePatient did not tolerate a higher dose regimen or a higher intensity statin.
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DISCUSSION
Periodic assessment of real-world clinical data on the manage-
ment of CV risk factors such as dyslipidemia is essential to 
gauge the effectiveness of disease management guidelines. In 
our study, aimed at ascertaining target LDL-C achievement in 
Korean patients with dyslipidemia, risk-stratified according to 
ESC/EAS (2011) guidelines, a substantial proportion of the 
study patients were already in the very high-risk category. Over-
all target LDL-C was achieved in less than half of the patients 
and this proportion was inversely associated with risk categori-
zation. We also discovered that study patients who were statin-
intolerant or had ACS/MI in the preceding 12 months had poor-
er target achievement rates in comparison to the other patients. 
Despite a large volume of clinical data and established guide-
lines from numerous medical associations, achieving target 
LDL-C levels in patients with dyslipidemia has been somewhat 
less than optimal and inconsistent across periods and regions. In 
one of the first large-scale, multinational studies conducted in 
almost 10,000 patients, the lipid treatment assessment project 2 
(LTAP2), the target achievement rate ranged between 47.0% 
and 84.0% [28]. Interestingly, this study also enrolled almost 
1,000 Korean patients in whom target achievement was report-
ed to be 83.5%, even though 68.0% of the patients were in the 
high-risk category according to the National Cholesterol Educa-
tion Program Adult Treatment Panel III guidelines [29]. The 
Dyslipidemia International Study (DYSIS) which was conduct-
ed in 30 countries and analyzed ≥50,000 patients who were 
risk-stratified according to the ESC/EAS (2011) guidelines, re-
ported a target achievement rate in between 14.3% and 49.5% 
[30]. In both the LTAP2 and DYSIS investigations, patients in 
the higher risk strata or with other CV comorbidities had a sub-
stantially lower target achievement rate. These findings have 
also been replicated in the Asian content by the Centralized Pan-
Regional Surveys on the Undertreatment of Hypercholesterol-
aemia (CEPHEUS) Pan-Asian study, which showed LDL-C 
target achievement in 49.4% of overall patients [31]. 
Attainment of lipid indices such as LDL-C have been clini-
cally validated to depend on various factors such as disease pro-
gression, time to diagnosis and commencement and intensifica-
tion of treatment regimens. Late detection of dyslipidemia, iner-
tia in timely and appropriate interventions, as well as presence 
of other CV comorbidities might also contribute to suboptimal 
reduction in LDL-C levels. As high physicians’ satisfaction 
(84.5% in overall) with the current LDL-C levels was revealed 
to be the prime reason for not prescribing high-intensity or high-
est dose of statins regardless of either accordance to guidelines 
recommendation or achieving risk-stratified LDL-C target lev-
els in this study, their physicians’ insufficient of awareness of 
guidelines might be the major factor of non-adherence to guide-
lines and, consequently, failure in achieving target LDL-C lev-
els [32-34]. In line with this hypothesis, physicians underesti-
mated the risk levels for 71.6% of all patients in this study and 
target achievement of LDL-C levels was only 44.3%. Moreover, 
the underestimation and target achievement of LDL-C rates 
were as high as 79.9% and as low as 39.0% among very high-
risk patients, respectively. Since a prerequisite for evidence-
based management of dyslipidemia is appropriate risk stratifica-
tion, the discordance in risk assessment could have a substantial 
bearing on the outcomes. For example, a recent study [35] 
showed that only 42.4% of the patients who were recommended 
for statin therapy were on the recommended statin intensity. In 
the study, untreated (25.3%) and undertreated (32.3%) patients 
had significantly higher LDL-C levels than the ones on recom-
mended statin intensity. Interestingly, another recent study re-
vealed that Korean cardiologists tend to be more determined in 
LMTs and achieve higher goal attainment rate than other Asian 
cardiologists in the CEPHEUS study [36]. Further investigation 
would be needed to identify factors influencing physician’s 
stratification of CV risk and adherence to guidelines’ recom-
mendation for statin intensity especially in Korea.
Given the complex nature of metabolic disease and its rela-
tion to CVD, it is practically impossible for a single study to de-
cipher all relevant and multimodal pathways involved. The goal 
of our study was to answer one key practical question—what is 
the rate of LDL-C target achievement in Korean patients in real-
world settings? Certain aspects of dyslipidemia treatment were 
beyond the scope of our study; we could not ascertain patient 
adherence, a factor critical to any chronic therapy. Moreover, no 
follow-up visits were planned in the study to monitor patients 
for changes in LDL-C levels. We were also unable to ascertain 
specific treatments or regimens that were more successful than 
others in helping patients achieve their LDL-C targets. Howev-
er, the overall findings of our study not only serve to reiterate 
the suboptimal attainment of LDL-C reduction in Korean pa-
tients presenting CV risk but also highlights the need to revise 
current practices in management of dyslipidemia in Korea. Fur-
ther studies will need to be conducted in order to fine tune the 
existing guidelines for successfully lowering the CV risk posed 
by dyslipidemia in the Korean population.  
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